Diarrhea News and Research

Latest Diarrhea News and Research

Annual treated wastewater in North America roughly equals volume of Niagara Falls; less than 4% is reused

Amid growing competition for freshwater from industry and cities, coupled with a rising world shortage of potash, nitrogen and phosphorus, an international study predicts a rapid increase in the use of treated wastewater for farming and other purposes worldwide.

7 Sep 2013

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.

7 Sep 2013

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

7 Sep 2013

UCLA researchers explain Post-Diverticulitis Irritable Bowel Syndrome

UCLA researchers have described a new form of irritable bowel syndrome that occurs after an acute bout of diverticulitis, a finding that may help lead to better management of symptoms and relief for patients.

6 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Actavis South Atlantic LLC and Actavis, Inc. (collectively, "Actavis") to resolve pending patent litigation in response to Actavis' abbreviated new drug application seeking approval to market generic versions of Avanir's NUEDEXTA (dextromethorphan hydrobromide/quinidine sulfate) capsules.

4 Sep 2013

European Commission approves Stivarga tablets for treatment of patients with mCRC

Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the European Commission has approved Stivarga® (regorafenib) tablets for the treatment of adult patients with metastatic colorectal cancer (mCRC).

30 Aug 2013

Texas A&M University biologist receives federal grant to study Clostridium difficile

A Texas A&M University biologist has received a federal grant to study the fecal samples of hundreds of people to better understand the gut bacteria Clostridium difficile - the cause of some 14,000 deaths a year in America - and to help lay the basic science foundation to develop drugs to combat its deadly results.

30 Aug 2013

Experts share tips on preventing ovarian cancer

Ovarian cancer is the fourth leading cause of death in American women. Approximately 22,000 women are diagnosed annually and 14,000 die from the disease. September is Ovarian Cancer Awareness month and Mount Sinai experts are sharing tips on prevention.

29 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.

27 Aug 2013

Review Article examines FMT methodology as effective treatment for C. difficile infection

Fecal microbiota transplantation has emerged as a highly effective treatment for recurrent Clostridium difficile infection, with very early experience suggesting that it may also play a role in treating other gastrointestinal and non-GI diseases.

23 Aug 2013

New radiation treatment can reduce bone pain, extend lives of prostate cancer patients

Prostate cancer that has spread to the bones can cause pain and fractures. Loyola University Medical Center is among the first hospitals in Chicago to offer a new targeted radiation treatment that can reduce bone pain and the incidence of fractures - and also extend patients' lives.

23 Aug 2013

Nuvo: FDA accepts to review New Drug Application for PENNSAID 2%

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensee for PENNSAID (diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt has advised that the U.S. Food and Drug Administration has accepted for filing and review the New Drug Application for PENNSAID 2% submitted by Mallinckrodt on August 7, 2013.

22 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

Probiotic does not prevent clinical relapse in patients with Crohn's disease

Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

16 Aug 2013

Risk of infectious gastroenteritis and IBD relapse increases during heat wave periods

Swiss researchers report an increase risk of inflammatory bowel disease (IBD) relapse in patients during heat wave periods. The study published in The American Journal of Gastroenterology also found an increase of infectious gastroenteritis during heat waves, with the strongest impact following a 7 day lag time after the heat wave.

14 Aug 2013

Multiple sclerosis patients see "rapid expansion" of effective new treatment options

After decades of research, multiple sclerosis patients are seeing a "rapid expansion" of effective new treatment options, according to a review article in the journal Neurologic Clinics.

14 Aug 2013

Diarrhea News and Research

Latest Diarrhea News and Research

Annual treated wastewater in North America roughly equals volume of Niagara Falls; less than 4% is reused

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

UCLA researchers explain Post-Diverticulitis Irritable Bowel Syndrome

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

European Commission approves Stivarga tablets for treatment of patients with mCRC

Texas A&M University biologist receives federal grant to study Clostridium difficile

Experts share tips on preventing ovarian cancer

FDA grants Priority Review designation to sNDA for Nexavar tablets

FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

Review Article examines FMT methodology as effective treatment for C. difficile infection

New radiation treatment can reduce bone pain, extend lives of prostate cancer patients

Nuvo: FDA accepts to review New Drug Application for PENNSAID 2%

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Probiotic does not prevent clinical relapse in patients with Crohn's disease

Risk of infectious gastroenteritis and IBD relapse increases during heat wave periods

Multiple sclerosis patients see "rapid expansion" of effective new treatment options

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in